Literature DB >> 19047309

Lack of association of soluble CD40 ligand with the presence of acute myocardial infarction or ischemic stroke in the emergency department.

Michaela Plaikner1, Andreas Peer, Gerda Falkensammer, Christoph Schmidauer, Christoph Pechlaner, Andrea Griesmacher, Otmar Pachinger, Johannes Mair.   

Abstract

BACKGROUND: Soluble CD40 ligand (sCD40L) has been proposed as a new risk marker for cardiovascular diseases; however, its possible role as a diagnostic marker in the emergency department (ED) has not yet been investigated.
METHODS: We investigated sCD40L for the diagnosis of acute myocardial infarction or ischemic stroke in 1089 consecutive patients (525 males, 564 females; age, 17-98 years; median, 56 years) in an ED treating mainly adults with medical or neurologic emergencies. We used a research assay from Roche Diagnostics to measure sCD40L in heparinized plasma prepared from routinely drawn blood samples.
RESULTS: Intraassay and interassay CVs in our laboratory ranged from 1.6%-4.2% and from 4.4%-4.9%, respectively. A multiple linear regression analysis revealed sCD40L concentration to be significantly associated with C-reactive protein concentration (P = 0.012) and platelet count (P < 0.001). In addition, a subgroup analysis revealed a significant association between smoking and sCD40L concentration (P = 0.006). All other tested variables, including discharge diagnosis, age, sex, and other laboratory variables, showed no significant associations.
CONCLUSIONS: In adults presenting to the ED, sCD40L is not useful as a diagnostic marker for acute cardiac, cerebrovascular ischemic, or thromboembolic events.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19047309     DOI: 10.1373/clinchem.2008.114231

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

Review 1.  Obstructive sleep apnea syndrome: blood viscosity, blood coagulation abnormalities, and early atherosclerosis.

Authors:  Domenico Maurizio Toraldo; Francesco Peverini; Michele De Benedetto; Francesco De Nuccio
Journal:  Lung       Date:  2012-10-18       Impact factor: 2.584

Review 2.  Novel biomarkers for cardiovascular risk prediction.

Authors:  Juan Wang; Guo-Juan Tan; Li-Na Han; Yong-Yi Bai; Miao He; Hong-Bin Liu
Journal:  J Geriatr Cardiol       Date:  2017-02       Impact factor: 3.327

3.  Evidence and Cost Effectiveness Requirements for Recommending New Biomarkers.

Authors:  Paul Collinson
Journal:  EJIFCC       Date:  2015-08-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.